Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
jRCT2051200145Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tenapanor in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Change in serum phosphorus at Week 8. Started Mar 2021; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2051200145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200145.